Customized Extracellular Vesicles For Preventative And Therapeutic Solutions
Ciloa focus on the production of membrane proteins derived from extracellular vesicles for the purpose of developing novel drugs, therapeutic monoclonals, vaccines and, novel anti-infective preventative vaccines.
Prior to running Ciloa as CEO, Dr Mamoun was a Director at the CNRS/Montpellier University, focusing on antibody and vaccine development. Dr Mamoun also served as the Director of Research at INSERM and was responsible for technology transfer. Prior to this, Dr Mamoun had an extensive career covering various different roles at INSERM focusing on exosomes and a wide variety of virology research themes.
Dr. Robert Mamoun, CEO of Ciloa